# US 2023/0398122 A1 · Methods of treating b-cell proliferative disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398122 A1
- Document ID: US20230398122A1
- Status: Published application
- Kind: A1
- Application number: 18/206,290
- Filed: 2023-06-06
- Published: 2023-12-14
- Earliest claimed: 2022-06-08
- Assignees: BeiGene Switzerland GmbH
- Applicants: BeiGene Switzerland GmbH
- Inventors: Jason PAIK; Tommi SALMI; Ying OU
- Web page: https://patentgrep.com/patent/US20230398122A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

## Claims

### Claim 1

A method of treating or delaying progression of a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer, the method comprising
concomitantly administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a dose of about 320 mg twice a day, and the moderate CYP3A inducer,
wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL); and
the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).

### Claim 3 (depends on 2)

The method of claim 2, wherein the moderate CYP3A inducer is rifabutin.

### Claim 4 (depends on 1)

The method of claim 1, wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL).

### Claim 5 (depends on 1)

The method of claim 1, wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM).

### Claim 6 (depends on 1)

The method of claim 1, wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL).

### Claim 7 (depends on 1)

The method of claim 1, wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL).

### Claim 8 (depends on 1)

The method of claim 1, wherein the moderate CYP3A inducer is rifabutin.

### Claim 9

A method of treating or delaying progression of a B-cell proliferative disorder in a patient, the method comprising
selecting the patient who is being treated with a moderate CYP3A inducer; and
concomitantly administering to the selected patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a dose of about 320 mg twice a day and the moderate CYP3A inducer,
wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL).

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The method of claim 9, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).

### Claim 12 (depends on 9)

The method of claim 9, wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL).

### Claim 13 (depends on 9)

The method of claim 9, wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM).

### Claim 14 (depends on 9)

The method of claim 9, wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL).

### Claim 15 (depends on 9)

The method of claim 9, wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL).

### Claim 16 (depends on 9)

The method of claim 9, wherein the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin.

### Claim 17 (depends on 16)

The method of claim 16, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).

### Claim 18 (depends on 17)

The method of claim 17, wherein the moderate CYP3A inducer is rifabutin.

### Claim 19

A method of treating or delaying progression of a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer, the method comprising
assessing the patient as to whether the patient can avoid being treated with the moderate CYP3A inducer;
selecting the patient who cannot avoid being treated with the moderate CYP3A inducer; and
concomitantly administering to the selected patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a dose of about 320 mg twice a day, and the moderate CYP3A inducer,
wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL).

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The method of claim 19, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).

### Claim 22 (depends on 19)

The method of claim 19, wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL).

### Claim 23 (depends on 19)

The method of claim 19, wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM).

### Claim 24 (depends on 19)

The method of claim 19, wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL).

### Claim 25 (depends on 19)

The method of claim 19, wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL).

### Claim 26 (depends on 19)

The method of claim 19, wherein the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin.

### Claim 27 (depends on 26)

The method of claim 26, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL).

### Claim 28 (depends on 27)

The method of claim 27, wherein the moderate CYP3A inducer is rifabutin.

### Claim 29 (depends on 9)

The method of claim 9, wherein the B-cell proliferative disorder is diffuse large B-cell lymphoma (DLBCL).

### Claim 30 (depends on 19)

The method of claim 19, wherein the B-cell proliferative disorder is diffuse large B-cell lymphoma (DLBCL).
